Elicio Therapeutics (ELTX) Convertible Debt (2024)
Elicio Therapeutics posted quarterly Convertible Debt of $20.0 million for Q4 2024, up 1.0% on a QoQ basis from $19.8 million in Q3 2024.
Elicio Therapeutics (ELTX) has 1 years of Convertible Debt data on file, last reported at $20.0 million in Q4 2024.
- For the quarter ending Q4 2024, Convertible Debt changed N/A year-over-year to $20.0 million; the trailing twelve-month figure through Dec 2024 stood at $20.0 million (changed N/A YoY), and the FY2024 full-year result was $20.0 million, changed N/A from the prior year.
- Convertible Debt for Q4 2024 stood at $20.0 million, up from $19.8 million in the prior quarter.
- Across five years, Convertible Debt topped out at $20.0 million in Q4 2024 and bottomed at $19.8 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 20.03 Mn |
| Sep 30, 2024 | 19.84 Mn |